Back to search results

Targeted Genomic Analysis for Cancer

This study is looking at how analyzing your blood and tissue samples can help doctors understand your cancer better. Researchers will use a method called genomic sequencing to look at the genetic makeup of your cancer cells. This can help find changes in your genes that might be important for cancer development. The goal is to improve how doctors diagnose and treat rare cancers, especially those that are hard to treat with standard therapies. This study will follow participants for up to 15 years to see how these genetic findings relate to treatment outcomes.

Study design
This is an observational study, meaning researchers will collect and analyze samples without giving new treatments. It aims to enroll 1100 participants.
What's involved
You would provide previously collected tissue samples and may also have blood samples taken. You will be followed up every 3 months for 2 years, then every 6 months for 15 years.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed up every 3 months for 2 years, and then every 6 months for up to 15 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02688517

Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer

Recruiting
Not specifiedAges 1+Observational
Rutgers, The State University of New Jersey
~1,100 participants
Updated 2026-04-17 on ClinicalTrials.gov
What's tested:Cytology Specimen Collection ProcedureLaboratory Biomarker Analysis

At a glance

Recruiting sites
2 of 11 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequencies of individual specific mutations and combinations of mutations of related pathway genes
Measured over Up to 15 years
+1 more outcome measured

Conditions

Malignant Neoplasm

Explore related trials

Malignant Neoplasm

Where it's being run

11 sites across 2 states
New Jersey10
Wisconsin1

Study leadership

  • Shridar Ganesan · PRINCIPAL_INVESTIGATOR · Rutgers Cancer Institute of New Jersey

Who to contact

Clinical Trials Office
732-235-2465
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Karnofsky/Lansky performance score \>= 30
A signed written informed consent
Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment
Paraffin blocks of the patient's tumor tissue are available and accessible for analysis

Exclusion

Karnofsky/Lansky performance score \< 30
Life expectancy \< 3 months

What this trial measures

  • Frequencies of individual specific mutations and combinations of mutations of related pathway genesUp to 15 years

    Descriptive analysis will be used to determine frequencies of specific mutations and to determine the pathways that can be targeted most frequently in patients with rare/poor prognosis cancer.

  • Rate of actionable mutations in rare and/or poor prognosis cancersUp to 15 years

    The actual rate of mutations found in this study will be determined to estimate the true underlying mutation rate.